



FTW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

MAIER et al.

Appl. No.: 10/591,477 ✓

Filing Date: September 1, 2006

Intl. Appl. No.: PCT/EP2005/051086

Intl. Filing Date: March 10, 2005 (10.03.2005)

Title: **NOVEL SULFONYLPYRROLES**

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:


1. Information Disclosure Statement; and
2. PTO Form-1449 with 55 references cited, and copies of 51 of the 55 references cited.

The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account No. 14-0112.

Respectfully submitted,
NATH & ASSOCIATES PLLC

December 21, 2006

By:


Gary M. Nath, Reg. No. 26,965
Sheldon M. McGee, Reg. No. 50,454
Customer No. 34375

Le



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

MAIER et al.

Appl. No.: 10/591,477

Filing Date: September 1, 2006

Intl. Appl. No.: PCT/EP2005/051086

Intl. Filing Date: March 10, 2005 (10.03.2005)

Title: **NOVEL SULFONYLPYRROLES**

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. 1.97-1.98. Please note the following particulars: [NOTE: One only of items a, b, c, and d must be checked.]

a. ☒ [XXX] The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.

b. ☐ [] The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311.
The enclosed statement is accompanied by [check one]:
☐ [] i. a certification in part (e) below as specified in 37 C.F.R. 1.97(e), or
☐ [] ii. a check in the amount required by 37 C.F.R. 1.17(p).

c. ☐ [] The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311, but before payment of the issue fee.
☐ [] Certification report(e) below; and
☐ [] a check in the amount as required by 1.17(p).

d. ☐ The enclosed statement is being filed pursuant to 37 C.F.R. 1.97(i), for placement in the file.

e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

☐ I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,

or

☐ I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or

☐ Appropriate certification is attached.

f. [XXX] If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

g. [XXX] Copies of the documents are attached herewith with a completed Form PTO-1449.

Or

☐ Copies of the documents are not attached as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:

and / or

[XXX] Copies of US Patents/Publications not attached as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,
NATH & ASSOCIATES PLLC

December 21, 2006

By: 

Gary M. Nath, Reg. No. 26,965
Sheldon M. McGee, Reg. No. 50,454
Customer No. 34375

ct

PTO FORM-1449 INFORMATION DISCLOSURE CITATION		Inventor(s): MAIER et al.					
		Appl. No.: 10/591,477		Intl. Appl. No.: PCT/EP2005/051086		Art Unit: UNKNOWN	
		Filing Date: September 1, 2006		Intl. Filing Date: March 10, 2005		Examiner: UNKNOWN	
U.S. PATENT DOCUMENTS							
Exam. Initial		Document No.	Issue/Public. Date	Inventor	Filing Date		
	A1	6,432,999	13 Aug 2002	Talley et al.	11 Jun 2001		
	A2	4,960,787	02 Oct 1990	Wasley	06 Feb 1989		
	A3	2005/0234033	20 Oct 2005	Anandan et al.	01 Apr 2005		
	A4	2005/0288282	29 Dec 2005	Delorme et al.	25 Mar 2005		
FOREIGN PATENT DOCUMENTS							
Exam. Initial		Document No.	Public. Date	Country	Translation		
	A5	0 570 594 A1	24 Nov 1993	EP	n/a		
	A6	1 431 267 A1	23 Jun 2004	EP	n/a		
	A7	2004/046094 A1	03 Jun 2004	WO	n/a		
	A8	2005/020921 A2	10 Mar 2005	WO	n/a		
	A9	01/38322 A1	31 May 2001	WO	n/a		
	A10	2005/086898 A2	22 Sep 2005	WO	n/a		
	A11	2004/037751 A2	06 May 2004	WO	n/a		
	A12	03/024448 A2	27 Mar 2003	WO	n/a		
OTHER							
Exam. Initial		(Including Author, Title, Date, Pertinent Pages, etc.)					
	A13	J. Almenara et al. "Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)". <u>Leukemia</u> , vol.16, pp.1331-1343, 2002.					
	A14	G. Bouchain et al. "Development of Potential Antitumor Agents. Synthesis and Biological Evaluation of a New Set of Sulfonamide Derivatives as Histone Deacetylase Inhibitors". <u>J. Med. Chem.</u> , vol.46, pp.820-830, 2003.					
	A15	Y.L. Chung et al. "A Therapeutic Strategy Uses Histone Deacetylase Inhibitors to Modulate the Expression of Genes Involved in the Pathogenesis of Rheumatoid Arthritis". <u>Molecular Therapy</u> , vol.8, pp. 707-717, 2003.					
	A16	P. Dhordain et al. "The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression". <u>Nucleic Acids Research</u> , vol.26, No.20, pp.4645-4651, 1998.					
	A17	W. Fischle et al. "Enzymatic Activity Associated with Class II HDACs is Dependent on a Multiprotein Complex Containing HDAC3 and SMRT/N-CoR". <u>Molecular Cell</u> , vol.9, pp.45-58, 2002.					
	A18	L. Gao et al. "Cloning and Functional Characterization of HDAC11, a Novel Member of the Human Histone Deacetylase Family". <u>J. Biol. Chem.</u> , vol.277, No.28, pp.25748-25755, 2002.					
	A19	P. George et al. "Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3". <u>Blood</u> , vol.105, pp.1768-1777, 2005.					
	A20	K.B. Glaser et al. "Role of Class I and Class II histone deacetylases in carcinoma cells using siRNA". <u>Biochemical and Biophysical Research Communications</u> , vol.310, pp.529-536, 2003.					
	A21	S. Haggarty et al. "Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation". <u>J. Proc. Natl. Acad. Sci. USA</u> , vol.100, No.8, pp.4389-4394, 2003.					
	A22	L.Z. He et al. "Distinct interactions of PML-RAR α and PLZF-RAR α with co-repressors determine differential responses to RA in APL". <u>Nature Genetics</u> , vol.18, pp.126-135, 1998.					
	A23	E. Hockly et al. "Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease". <u>J. Proc. Natl. Acad. Sci. USA</u> , vol.100, No.4, pp.2041-2046, 2003.					

PTO FORM-1449 INFORMATION DISCLOSURE CITATION		Inventor(s): MAIER et al.		
		Appl. No.: 10/591,477	Intl. Appl. No.: PCT/EP2005/051086	Art Unit: UNKNOWN
		Filing Date: September 1, 2006	Intl. Filing Date: March 10, 2005	Examiner: UNKNOWN
OTHER (Cont.)				
A24	R.W. Johnstone et al. "Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target?". <u>Cancer Cell</u> , vol.4, pp.13-18, 2003.			
A25	S. Khochbin et al. "Functional significance of histone deacetylase diversity". <u>Current Opinion Gen. Dev.</u> , vol.11, pp.162-166, 2001.			
A26	M.S. Kim et al. "Inhibition of Histone Deacetylase Increases Cytotoxicity to Anticancer Drugs Targeting DNA". <u>Cancer Research</u> , vol.63, pp.7291-7300, 2003.			
A27	O.H. Kraemer et al. "Histone deacetylase as a therapeutic target". <u>Trends In Endocrin. & Metabol.</u> , vol.12, No.7, pp.294-300, 2001.			
A28	G. Lagger et al. "Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression". <u>EMBO</u> , vol.21, pp.2672-2681, 2002.			
A29	F. Leoni et al. "The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines". <u>Proc. Natl. Acad. Sci. USA</u> , vol.99, No.5, pp.2995-3000, 2002.			
A30	A. Mai et al. "3-(4-Aroyl-1-methyl-1 H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 1. Design, Synthesis, Biological Evaluation, and Binding Mode Studies Performed through Three Different Docking Procedures". <u>J. Med. Chem.</u> , vol.46, pp.512-524, 2003.			
A31	A. Mai et al. "3-(4-Aroyl-1-methyl-1 H-2-pyrrolyl)-N-hydroxy-2-propenamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 2. Effect of Pyrrole-C ₂ and/or -C ₄ Substitutions on Biological Activity". <u>J. Med. Chem.</u> , vol.47, pp.1098-1109, 2004.			
A32	P.A. Marks et al. "Histone Deacetylases and Cancer: Causes and Therapies". <u>Nature Reviews</u> , vol.1, pp.194-202, 2001.			
A33	T.A. Miller et al. "Patent status of histone deacetylase inhibitors". <u>Expert Opin. Ther. Patents</u> , vol.14, No.6, pp.791-804, 2004.			
A34	T.A. Miller et al. "Histone Deacetylase Inhibitors". <u>J. of Med. Chem.</u> , vol.46, No.24, pp.5098-5116, 2003.			
A35	N. Mishra et al. "Histone deacetylase inhibitors modulate renal disease in the MRL- <i>lpr/lpr</i> mouse". <u>J. Clin. Invest.</u> , vol.111, pp.539-552, 2003.			
A36	C.S. Mitsiades et al. "Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications". <u>Proc. Natl. Acad. Sci. USA</u> , vol.101, No.2, pp.539-552, 2004.			
A37	P.N. Munster et al. "The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Induces Differentiation of Human Breast Cancer Cells". <u>Cancer Research</u> , vol.61, pp.8492-8497, 2001.			
A38	T. Murata et al. "Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein-Taybi syndrome". <u>Human Molecular Genetics</u> , vol.10, No.10, pp.1071-1076, 2001.			
A39	T. Nakayama et al. "Epigenetic Regulation of Androgen Receptor Gene Expression in Human Prostate Cancers". <u>Lab. Inv.</u> , vol.80, No.12, pp.1789-1796, 2000.			
A40	R. Nimmanapalli et al. "Histone Deacetylase Inhibitor LAQ824 Both Lowers Expression and Promotes Proteasomal Degradation of Bcr-Abl and Induces Apoptosis of Imatinib Mesylate-sensitive or -refractory Chronic Myelogenous Leukemia-Blast Crisis Cells". <u>Cancer Research</u> , vol.63, pp.5126-5135, 2003.			
A41	K. Nishida et al. "Histone Deacetylase Inhibitor Suppression of Autoantibody-Mediated Arthritis in Mice via Regulation of p16 ^{INK4a} and p21 ^{WAF1/Cip1} Expression". <u>Arthritis Rheumatism</u> , vol.50, No.10, pp.3365-3376, 2004.			
A42	R.L. Piekarz et al. "Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report". <u>Blood</u> , vol.98, pp.2865-2868, 2001.			
A43	R. Ragno et al. "3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 3. Discovery of Novel Lead Compounds through Structure-Based Drug Design and Docking Studies". <u>J. Med. Chem.</u> , vol.47, pp.1351-1359, 2004.			
A44	C.M. Reilly et al. "Modulation of Renal Disease in MRL/ <i>lpr</i> Mice by Suberoylanilide Hydroxamic Acid". <u>J. Immunol.</u> , vol.173, pp.4171-4178, 2004.			

PTO FORM-1449 <u>INFORMATION DISCLOSURE</u> <u>CITATION</u>		Inventor(s): MAIER et al.		
		Appl. No.: 10/591,477	Intl. Appl. No.: PCT/EP2005/051086	Art Unit: UNKNOWN
		Filing Date: September 1, 2006	Intl. Filing Date: March 10, 2005	Examiner: UNKNOWN
OTHER (Cont.)				
	A45	S.W. Remiszewski et al. "Recent advances in the discovery of small molecule histone deacetylase inhibitors". <u>Current Opin. Drug Disc. Development</u> , vol.5, No.4, pp.487-499, 2002.		
	A46	A.J. Ruijter et al. "Histone deacetylases (HDACs): characterization of the classical HDAC family". <u>Biochem. J.</u> , vol.370, pp.737-749, 2003.		
	A47	V. Sandor et al. "P21-dependent G ₁ arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228". <u>British J. of Cancer</u> , vol.83, No.6, pp.817-825, 2000.		
	A48	J.S. Steffan et al. "Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in <i>Drosophila</i> ". <u>Nature</u> , vol.413, pp.739-743, 2001.		
	A49	B.D. Strahl et al. "The language of covalent histone modifications". <u>Nature</u> , vol.403, pp.41-45, 2000.		
	A50	T. Tatamiya et al. "Isozyme-selective activity of the HDAC inhibitor MS-275". AACR Annual Meeting [Abstract 2451], 2004.		
	A51	C. Van Lint et al. "The Expression of a Small Fraction of Cellular Genes Is Changed in Response to Histone Hyperacetylation". <u>Gene Expression</u> , vol.5, pp.245-253, 1996.		
	A52	E. Verdin et al. "Class II histone deacetylases: versatile regulators". <u>Trends in Genetics</u> , vol.19, No.5, pp.286-293, 2003.		
	A53	J. Wang et al. "ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex". <u>Proc. Natl. Acad. Sci. USA</u> , vol.95, pp.10860-10865, 1998.		
	A54	X. Yang et al. "Transcriptional Activation of Estrogen Receptor α in Human Breast Cancer Cells by Histone Deacetylase Inhibition". <u>Cancer Research</u> , vol.60, pp.6890-6894, 2000.		
	A55	P. Zhu et al. "Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis". <u>Cancer Cells</u> , vol.5, pp.455-463, 2004.		
Examiner		Date Considered		
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP'609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.				